In vitro susceptibilities of aerobic and facultatively anaerobic Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: 2004 results from SMART (Study for Monitoring Antimicrobial Resistance Trends)

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 205-210

  Rossi, Flávia ^a   Baquero, Fernando ^b   Hsueh, Po Ren ^c   Paterson, David L ^d   Bochicchio, Grant V ^e   Snyder, Theresa A ^f   Satishchandran, Vilas ^f   McCarroll, Kathleen ^f   DiNubile, Mark J ^f   Chow, Joseph W ^f  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL RAMÓN Y CAJAL   (Spain)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^e UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antimicrobial susceptibility; Enterobacteriaceae; ESBLs; Extended spectrum lactamases; In vitro susceptibility

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN;

ABDOMINAL INFECTION; AEROBIC BACTERIUM; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; ASIA; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONTROLLED STUDY; DILUTION; ENTEROBACTER; ENTEROBACTERIACEAE; ESCHERICHIA COLI; GRAM NEGATIVE FACULTATIVELY ANAEROBIC RODS; HUMAN; IN VITRO STUDY; KLEBSIELLA; NONHUMAN; PHENOTYPE; PRACTICE GUIDELINE; SOUTH AND CENTRAL AMERICA;

ABDOMEN; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS;

EID: 33748044288     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl199     Document Type: Article

References (10)

1. Paterson DL, Rossi F, Baquero F et al. In vitro susceptibilities of aerobic and facultative Gram-negative bacilli isolated from patients with intra-abdominal infections worldwide: The 2003 Study for Monitoring Antimicrobial Resistance Trends (SMART). J Antimicrob Chemother 2005; 55: 965-73.
2. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Thirteenth Informational Supplement M100-S13. NCCLS, Villanova, PA, USA, 2003.
3. Miettinen O, Nurminen M. Comparative analysis of two rates. Stat Med 1985; 4: 213-26.
4. Lautenbach E, Strom BL, Nachamkin I et al. Longitudinal trends in fluoroquinolone resistance among Enterobacteriaceae isolates from inpatients and outpatients, 1989-2000: Differences in the emergence and epidemiology of resistance across organisms. Clin Infect Dis 2004; 38: 655-62.
5. Lautenbach E, Metlay J, Bilker WB et al. Association between fluoroquinolone resistance and mortality in Escherichia coli and Klebsiella pneumoniae infections: The role of inadequate empirical antimicrobial therapy. Clin Infect Dis 2005; 41: 923-9.
6. Stürenburg E, Mack D. Extended-spectrum β-lactamases: Implications for the clinical microbiology laboratory, therapy, and infection control. J Infect 2003; 47: 273-95.
7. Song W, Moland ES, Hanson ND et al. Failure of cefepime therapy in treatment of Klebsiella pneumoniae bacteremia. J Clin Microbiol 2005; 43: 4891-4.
8. Komatsu M, Aihara M, Shimakawa K et al. Evaluation of MicroScan ESBL confirmation panel for Enterobacteriaceae-producing, extended-spectrum β-lactamases isolated in Japan. Diagn Microbiol Infect Dis 2003; 46: 125-30.
9. Stürenburg E, Sobottka I, Noor D et al. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum β-lactamases in an Enterobacteriaceae strain collection. J Antimicrob Chemother 2004; 54: 134-8.
10. Oteo J, Campos J, Baquero F et al. Antibiotic resistance in 1962 invasive isolates of Escherichia coli in 27 Spanish hospitals participating in the European Antimicrobial Resistance Surveillance System (2001). J Antimicrob Chemother 2002; 50: 945-52.